Clay Siegall is the face of Seattle Genetics and the force that has led to many of the Pharmaceutical Company’s groundbreaking achievements. He has come a long way in making Seattle Genetics what it is today and the future seems to be getting brighter.
Clay Siegall is a co-founder, CEO and President of Seattle Genetics, a Drug Research Center that is instrumental in the research and discovery of newer cancer treatment solutions. He is also the chairman of company’s Board of Directors, a keynote position that has helped him secure several grants to fund their cancer research projects.
Mr. Siegall is a passionate contributor to the cancer research community. He has dedicated an entire career to finding tangible solutions for the cure or alleviation of cancer cases, especially lymphoma patients. Before joining Seattle Genetics, Clay had a 6-year contract with the National Cancer Institute before moving to the National Institute of Health where he worked for 3 years. In this period, he studied cancer cases which were crucial in laying down a path for his journey to developing one of the most lucrative cancer treatment drug in the US and Canadian market right now.
Seattle Genetics is currently pushing their main drug, Adcetris. Adcetris is the Drug Center’s flagship drug that works as an alternative treatment for patients with advanced lymphoma. Seattle Genetics raked in an estimated $325milion on the premier of Adcetris, and is on the verge of making it an FDA-approved commercial drug for lymphoma treatment.
Mr. Siegall played the biggest role in Seattle Genetics’ headline achievement with Adcetris. As the Chairman of the pharmaceutical company’s board, he garnered over $1.2 billion in funds from both private and public investors drawn by the company’s IPO announcement in 2001. He then moved to seek licenses for the approval of Adcetris as a test drug for lymphoma. Under his guide, Seattle Genetics received the green light from major players in the field of health like Glaxo Smith Kline, Pfizer, Abbvie, and Genentech.
Currently, there is a possibility of Adcetris becoming commercially available as a lymphoma solution once their Echelon-1 trials on the drug are completed in 2017. This will definitely put Seattle Genetics on the global map, and Clay Siegall on the headlines as the crusader who made this achievement possible.